receve y e nerna ona ureau on e ruary . . ; original claims 1, 2, 17, 20, 33, 43, 48, 49, 51, 59 and 60 amended; remaining claims unchanged (19 page)]
1. (Amended) An isolated nucleic acid molecule comprising a nucleotide sequence that encodes a polypeptide comprising: (a) theaminoacidsequenceofSEQLDNO:3,SEQIDNO:5, SEQ ID
NO: 7, SEQ ID NO: 9, SEQ ID NO: 11, SEQIDNO: 13, SEQ ID NO: 15, SEQIDNO: 17, SEQ ID NO: 19, SEQ ID NO: 21, SEQ LD NO: 23, SEQ ID NO: 25, SEQ ID NO: 27, SEQ ID NO: 29, or SEQ ID NO: 31 ;
(b) the amino acid sequence of SEQ LD NO: 34, SEQ ID NO: 36, SEQ ID NO: 38, SEQ ID NO: 40, SEQ ID NO: 42, SEQ ID NO: 44, SEQ LD NO: 46, SEQ ID NO:
48, SEQ LD NO: 50, SEQ ID NO: 52, SEQ LD NO: 54, or SEQ ID NO: 56;
(c) the amino acid sequence of SEQ ID NO: 59, SEQ ID NO: 61, SEQ ID NO: 63, SEQ ID NO: 65, SEQ ID NO: 67, SEQ ID NO: 69, SEQ ID NO: 71, SEQ LD NO: 73, SEQ ID NO: 75, SEQ ID NO: 77, SEQ ID NO: 79, SEQ ID NO: 81, SEQ ID NO: 83, SEQ ID NO: 85, SEQ ID NO: 87, SEQ ID NO: 89, SEQ ID NO: 91, SEQ ID NO: 93, SEQ
ID NO: 95, SEQ ID NO: 97, SEQ ID NO: 99, SEQ ID NO: 101, SEQ ID NO: 103, SEQ ID NO: 105, SEQ ID NO: 107, SEQ ID NO: 109, SEQIDNO: 111, SEQ ID NO: 113, SEQ ID NO: 115, SEQIDNO: 117,SEQIDNO: 119,SEQIDNO: 121, SEQ ID NO: 123, SEQ ID NO: 125, SEQ ID NO: 127, SEQ ID NO: 129, SEQIDNO: 131. SEQIDNO: 133, SEQ ID NO: 135, SEQ ID NO: 137, SEQ ID NO: 139, SEQ ID NO: 141, SEQ ID NO: 143, SEQ ID
NO: 145, SEQ E) NO: 147, SEQIDNO: 149, SEQIDNO: 151, SEQ ID NO: 153, SEQ ID NO: 155, SEQ ID NO: 157, SEQ LD NO: 159, SEQ ID NO: 161, SEQ ID NO: 163, or SEQ ID NO: 165;
(d) the amino acid sequence of SEQ ID NO: 168, SEQ ID NO: 170, SEQ ID NO: 172, SEQ ID NO: 174, SEQ ID NO: 176, SEQ ID NO: 178, SEQ ID NO: 180, SEQ
ID NO: 182, SEQIDNO: 184, SEQIDNO: 186, SEQ ID NO: 188, SEQIDNO: 190, SEQ ID NO: 192, SEQ ID NO: 194, SEQ ID NO: 196, SEQ ID NO: 198, SEQ ID NO: 200, SEQ ID NO: 202, SEQ ID NO: 204, SEQ ID NO: 206, SEQ LD NO: 208, SEQ ID NO: 210, SEQ ID NO: 212, SEQ ID NO: 214, or SEQ LD NO: 216, or SEQ ID NO: 218; or (e) the amino acid sequence ofSEQLD NO: 221, SEQ ID NO: 223, SEQ
LD NO: 225, SEQ ID NO: 227, SEQ ID NO: 229, SEQ ID NO: 231, SEQ ID NO: 233, SEQ
118
ID NO: 235, SEQ ID NO: 237, SEQ LD NO: 239, SEQ ID NO: 241, SEQ ID NO: 243, SEQ ID NO: 245, SEQ ID NO: 247, SEQ ID NO: 249, SEQ ID NO: 251, SEQ ID NO: 253, SEQ ID NO: 255, SEQ LD NO: 257, SEQ LD NO: 259, SEQ ID NO: 261, SEQ ID NO: 263, SEQ ID NO: 265, or SEQ LD NO: 267.
2. (Amended) An isolated nucleic acid molecule comprising:
(a) the nucleic acid sequence of SEQ ID NO: 2, SEQ ID NO: 4, SEQ LD NO: 6, SEQ ID NO: 8, SEQ LD NO: 10, SEQ ID NO: 12, SEQ ID NO: 14, SEQ ID NO: 16, SEQ ID NO: 18, SEQ ID NO: 20, SEQ LD NO: 22, SEQ ID NO: 24, SEQ ID NO: 26, SEQ ID NO: 28, or SEQ LD NO: 30;
(b) the nucleic acid sequence of SEQ LD NO: 33, SEQ ID NO: 35, SEQ ID NO: 37, SEQ ID NO: 39, SEQ LD NO: 41, SEQ LD NO: 43, SEQ ID NO: 45, SEQ LD NO: 47, SEQ ID NO: 49, SEQ ID NO: 51, SEQ ID NO: SEQ ID NO: 53, or SEQ ID NO: 55;
(c) the nucleic acid sequence of SEQ ID NO: 58, SEQ ID NO: 60, SEQ ID NO: 62, SEQ ID NO: 64, SEQ ID NO: 66, SEQ ID NO: 68, SEQ ID NO: 70, SEQ ID NO:
72, SEQ ID NO: 74, SEQ ID NO: 76, SEQ LD NO: 78, SEQ ID NO: 80, SEQ ID NO: 82, SEQ ID NO: 84, SEQ ID NO: 86, SEQ ID NO: 88, SEQ ID NO: 90, SEQ ID NO: 92, SEQ ID NO: 94, SEQ ID NO: 96, SEQ ED NO: 98, SEQ ID NO: 100, SEQ ID NO: 102, SEQ ID NO: 104, SEQ ID NO: 106, SEQ ID NO: 108 SEQ ID NO: 1 10, SEQ ID NO: 112, SEQ ID NO: 114, SEQ ID NO: 116, SEQ ID NO: 118, SEQ ID NO: 120, SEQ ID NO: 122, SEQ ED
NO: 124, SEQ ID NO: 146, SEQ ED NO: 148, SEQ ID NO: 130, SEQ ID NO: 132, SEQ ED NO: 134, SEQ ED NO: 136, SEQ ED NO: 138, SEQ ED NO: 140, SEQ D NO: 142, SEQ ED NO: 144, SEQ ED NO: 146, SEQ ED NO: 148, SEQ ED NO: 150, SEQ ED NO: 152, SEQ ED NO: 154, SEQ ED NO: 156, SEQ ED NO: 158, SEQ ED NO: 160, SEQ ED NO: 162, or SEQ ED NO: 164;
(d) the nucleic acid sequence of SEQ ED NO: 167, SEQ ED NO: 169, SEQ ED NO: 171, SEQ ED NO: 173, SEQ ED NO: 175, SEQ ED NO: 177, SEQ ED NO: 179, SEQ ED NO: 181, SEQ ED NO: 183, SEQ ED NO: 185, SEQ ED NO: 187, SEQ ED NO: 189, SEQ ED NO: 191, SEQ ED NO: 193, SEQ ED NO: 195, SEQ ED NO: 197, SEQ ED NO: 199, SEQ ED NO: 201, SEQ ED NO: 203, SEQ ED NO: 205, SEQ ED NO: 207, SEQ ED NO: 209, SEQ
ED NO: 211, SEQ ED NO: 213, SEQ ED NO: 215, or SEQ ED NO: 217;
119
(e) the nucleic acid sequence of SEQ ID NO: 220, SEQ ED NO: 222, SEQ ID NO: 224, SEQ ED NO: 226, SEQ ID NO: 228, SEQ ED NO: 230, SEQ ED NO: 232, SEQ ED NO: 234, SEQ ED NO: 236, SEQ ED NO: 238, SEQ ED NO: 240, SEQ ID NO: 242, SEQ ID NO: 244, SEQ ID NO: 246, SEQ ID NO: 248, SEQ ED NO: 250, SEQ ED NO: 252, SEQ ID NO: 254, SEQ ID NO: 256, SEQ ID NO: 258, SEQ ID NO: 260, SEQ ID NO: 262, SEQ
ID NO: 264, or SEQ ID NO: 266; or
(f) the nucleic acid sequence of SEQ ID NO: 1 , SEQ ID NO: 32, SEQ ID NO: 57, SEQ ID NO: 166, or SEQ ID NO: 219.
3. An isolated nucleic acid molecule comprising a complement of the nucleic acid molecule of any one of Claims 1 and 2.
4. An isolated nucleic acid molecule which hybridizes to the nucleic acid molecule of Claim 3 under highly stringent conditions.
5. An isolated nucleic acid molecule which hybridizes to the nucleic acid molecule of Claim 3 under moderately stringent conditions.
6. The isolated nucleic acid molecule of Claim 4, wherein said isolated nucleic acid molecule encodes a protective sequence product.
7. The isolated nucleic acid molecule of Claim 5, wherein said isolated nucleic acid molecule encodes a protective sequence product.
8. A vector comprising the nucleic acid of any one of Claims 1 and 2.
9. The vector of claim 8, wherein said vector is a viral vector.
10. An expression vector comprising the nucleic acid of any one of Claims 1 and 2 operatively associated with a regulatory nucleic acid controlling the expression of the nucleic acid in a host cell.
120
11. A host cell genetically engineered to contain the nucleic acid of any one of Claims 1 and 2.
12. A host cell genetically engineered to express the nucleic acid of any one of Claims 1 and 2 operatively associated with a regulatory nucleic acid controlling expression of the nucleic acid in said host cell.
13. The host cell of Claim 12, wherein said host cell is a neuronal cell.
14. The host cell of Claim 13, wherein said neuronal cell is a PC- 12 cell or a primary dissociated neuron.
15. A transgenic, non-human animal which has been genetically engineered to contain a transgene comprising the nucleic acid of any one of Claims 1 and 2.
16. The transgenic, non-human animal of Claim 15, wherein the transgene is expressed.
17. An isolated polypeptide comprising: (a) the amino acid sequence of SEQ ED NO: 3, SEQ ID NO: 5, SEQ ID
NO: 7, SEQ ED NO: 9, SEQ ID NO: 11, SEQ ID NO: 13, SEQ ID NO: 15, SEQ ID NO: 17, SEQ ID NO: 19, SEQ ID NO: 21, SEQ ID NO: 23, SEQ ID NO: 25, SEQ ID NO: 27, SEQ ED NO: 29, or SEQ ED NO: 31;
(b) the amino acid sequence of SEQ ID NO: 34, SEQ ID NO: 36, SEQ ED NO: 38, SEQ ED NO: 40, SEQ ID NO: 42, SEQ ID NO: 44, SEQ ID NO: 46, SEQ ID NO:
48, SEQ ID NO: 50, SEQ ID NO: 52, SEQ ID NO: 54, or SEQ JD NO: 56;
(c) the amino acid sequence of SEQ ID NO: 59, SEQ JD NO: 61, SEQ ID NO: 63, SEQ ID NO: 65, SEQ JD NO: 67, SEQ ED NO: 69, SEQ ID NO: 71, SEQ ID NO: 73, SEQ ED NO: 75, SEQ ID NO: 77, SEQ ID NO: 79, SEQ ID NO: 81, SEQ JD NO: 83, SEQ ID NO: 85, SEQ ID NO: 87, SEQ JD NO: 89, SEQ ED NO: 91, SEQ JD NO: 93, SEQ
ID NO: 95, SEQ ID NO: 97, SEQ JD NO: 99, SEQ ED NO: 101, SEQ ID NO: 103, SEQ ID
121
O: 105, SEQ JD NO: 107, SEQ ID NO: 109, SEQ ID NO: 111, SEQ ID NO: 113, SEQ ID O: 115, SEQ ID NO: 117, SEQ ED NO: 119, SEQ ED NO: 121, SEQ 3D NO: 123, SEQ ED NO: 125, SEQ ED NO: 127, SEQ ID NO: 129, SEQ JD NO: 131, SEQ JD NO: 133, SEQ ED NO: 135, SEQ ED NO: 137, SEQ ED NO: 139, SEQ ED NO: 141, SEQ ED NO: 143, SEQ ED NO: 145, SEQ ID NO: 147, SEQ ED NO: 149, SEQ ED NO: 151, SEQ ED NO: 153, SEQ ED NO: 155, SEQ ED NO: 157, SEQ ED NO: 159, SEQ ED NO: 161, SEQ ED NO: 163, or SEQ ED NO: 165;
(d) the amino acid sequence of SEQ ED NO: 168, SEQ ED NO: 170, SEQ ID NO: 172, SEQ ID NO: 174, SEQ ED NO: 176, SEQ ED NO: 178, SEQ ID NO: 180, SEQ ID NO: 182, SEQ ID NO: 184, SEQ ED NO: 186, SEQ ED NO: 188, SEQ ED NO: 190, SEQ JD NO: 192, SEQ ID NO: 194, SEQ ID NO: 196, SEQ ID NO: 198, SEQ ID NO: 200, SEQ ID NO: 202, SEQ ED NO: 204, SEQ JD NO: 206, SEQ ED NO: 208, SEQ ED NO: 210, SEQ ID NO: 212, SEQ ID NO: 214, or SEQ ID NO: 216, or SEQ ID NO: 218; or
(e) the amino acid sequence of SEQ ID NO: 221, SEQ ID NO: 223, SEQ ID NO: 225, SEQ ID NO: 227, SEQ JD NO: 229, SEQ JD NO: 231, SEQ JD NO: 233, SEQ JD NO: 235, SEQ JD NO: 237, SEQ ED NO: 239, SEQ JD NO: 241, SEQ ID NO: 243, SEQ ED NO: 245, SEQ ID NO: 247, SEQ ED NO: 249, SEQ ED NO: 251, SEQ ID NO: 253, SEQ ID NO: 255, SEQ ID NO: 257, SEQ JD NO: 259, SEQ ED NO: 261, SEQ ID NO: 263, SEQ HD NO: 265, or SEQ ED NO: 267.
18. An isolated polypeptide comprising an amino acid sequence encoded by the isolated nucleic acid molecule of Claim 4.
19. An isolated polypeptide comprising an amino acid sequence encoded by the isolated nucleic acid molecule of Claim 5.
20. An isolated fusion polypeptide comprising a fusion peptide and an amino acid sequence comprising:
(a) the amino acid sequence of SEQ ID NO: 3, SEQ JD NO: 5, SEQ ID NO: 7, SEQ JD NO: 9, SEQ JD NO: 11, SEQ ED NO: 13, SEQ ID NO: 15, SEQ ID NO: 17,
122
SEQ ID NO: 19, SEQ ED NO: 21, SEQ ED NO: 23, SEQ ED NO: 25, SEQ ED NO: 27, SEQ LD NO: 29, or SEQ ED NO: 31 ;
(b) the amino acid sequence of SEQ ED NO: 34, SEQ ED NO: 36, SEQ ED NO: 38, SEQ ED NO: 40, SEQ ED NO: 42, SEQ D NO: 44, SEQ ED NO: 46, SEQ ED NO: 48, SEQ ED NO: 50, SEQ ED NO: 52, SEQ ED NO: 54, or SEQ ED NO: 56;
(c) the amino acid sequence of SEQ ED NO: 59, SEQ ED NO: 61, SEQ ED NO: 63, SEQ ED NO: 65, SEQ ED NO: 67, SEQ ED NO: 69, SEQ ED NO: 71, SEQ ED NO: 73, SEQ ED NO: 75, SEQ ID NO: 77, SEQ ED NO: 79, SEQ ED NO: 81, SEQ ED NO: 83, SEQ ED NO: 85, SEQ ED NO: 87, SEQ ED NO: 89, SEQ ED NO: 91, SEQ ED NO: 93, SEQ ED NO: 95, SEQ ED NO: 97, SEQ ED NO: 99, SEQ ED NO: 101, SEQ ED NO: 103, SEQ ED
NO: 105, SEQ ED NO 107, SEQ ED NO: 109, SEQ ED NO: 1 1 1, SEQ ED NO: 113, SEQ ED NO: 115, SEQ ED NO 117, SEQ ID NO: 1 19, SEQ ED NO: 121, SEQ ED NO: 123, SEQ ED NO: 125, SEQ ED NO 127, SEQ HD NO: 129, SEQ ED NO: 131, SEQ ID NO: 133, SEQ ED NO: 135, SEQ ED NO 137, SEQ ED NO: 139, SEQ ED NO: 141, SEQ ED NO: 143, SEQ ED NO: 145, SEQ JD NO 147, SEQ ED NO: 149. SEQ JD NO: 151, SEQ JD NO: 153, SEQ ED NO: 155, SEQ JD NO 157, SEQ ED NO: 159, SEQ JD NO: 161 , SEQ ED NO: 163, or SEQ
ED NO: 165;
(d) the amino acid sequence of SEQ ED NO: 168, SEQ ED NO: 170, SEQ ED NO: 172, SEQ ID NO: 174, SEQ ED NO: 176, SEQ ED NO: 178, SEQ ED NO: 180, SEQ ED NO: 182, SEQ ED NO: 184, SEQ ED NO: 186, SEQ ED NO: 188, SEQ ID NO: 190, SEQ HD NO: 192, SEQ ID NO: 194, SEQ ED NO: 196, SEQ ED NO: 198, SEQ ED NO: 200, SEQ ED NO: 202, SEQ ED NO: 204, SEQ ED NO: 206, SEQ ED NO: 208, SEQ ED NO: 210, SEQ ED NO: 212, SEQ ED NO: 214, or SEQ ED NO: 216, or SEQ ED NO: 218; or
(e) the amino acid sequence of SEQ ED NO: 221, SEQ ED NO: 223, SEQ ED NO: 225, SEQ ED NO: 227, SEQ ID NO: 229, SEQ ID NO: 231, SEQ HD NO: 233, SEQ ED NO: 235, SEQ ED NO: 237, SEQ ED NO: 239, SEQ ED NO: 241, SEQ ED NO: 243, SEQ ED NO: 245, SEQ JD NO: 247, SEQ JD NO: 249, SEQ ED NO: 251, SEQ JD NO: 253, SEQ ED NO: 255, SEQ ED NO: 257, SEQ ED NO: 259, SEQ JD NO: 261, SEQ ED NO: 263, SEQ ED NO: 265, or SEQ ED NO: 267.
123
21. An isolated fusion polypeptide comprising a fusion peptide and an amino acid sequence encoded by the isolated nucleic acid molecule of Claim 4.
22. An isolated fusion polypeptide comprising a fusion peptide and an amino acid sequence encoded by the isolated nucleic acid molecules of Claim 5.
23. An antibody which binds to the isolated polypeptide of Claim 17.
24. A method for diagnosing a protective sequence-mediated condition, disorder or disease in an individual comprising obtaining a biological sample from said individual; contacting said biological sample with the antibody according to claim 23; wherein if said antibody interacts with said biological sample, but does not interact with a biological sample from a control individual not undergoing a protective sequence-mediated condition, disorder or disease, then a protective sequence-mediated condition, disorder or disease has been diagnosed.
25. A diagnostic kit for detecting a protective sequence-mediated condition, disorder or disease in an individual comprising a reagent in suitable packaging, wherein said reagent comprises the antibody according to claim 23.
26. A method for treating, ameliorating or preventing a protective sequence- mediated condition, disorder or disease in an individual comprising administering to the individual a compound which modulates the function, activity, expression and/or level of a protective sequence in a cell, cells, tissue, organ, organism or individual.
27. The method of Claim 26, wherein the compound inhibits the function, activity, expression and/or level of a protective sequence in a cell, cells, tissue, organ, organism or individual.
124
28. The method of Claim 26, wherein the compound enhances or potentiates the function, activity, expression and/or level of a protective sequence in a cell, cells, tissue, organ, organism or individual.
29. The methods of any one of Claims 26-28, wherein the compound is selected from the group consisting of a small organic molecule, an antibody, a ribozyme, an antisense molecule, and combinations thereof.
30. The method of any one of Claims 26-28, wherein the protective sequence- mediated condition, disorder, or disease is a condition, disorder, or disease of the central nervous system.
31. The method of Claim 30, wherein the central nervous system condition is an ischemia-related condition.
32. The method of Claim 31 , wherein the central nervous system condition is a stroke.
33. The method of Claim 26, wherein the protective sequence encodes a polypeptide comprising:
(a) the amino acid sequence of SEQ ID NO: 3, SEQ ED NO: 5, SEQ ED NO: 7, SEQ HD NO: 9, SEQ ED NO: 11, SEQ ED NO: 13, SEQ JD NO: 15, SEQ ID NO: 17, SEQ DD NO: 19, SEQ HD NO: 21, SEQ ID NO: 23, SEQ ED NO: 25, SEQ ED NO: 27, SEQ ED NO: 29, or SEQ ED NO: 31 ; (b) the amino acid sequence of SEQ ED NO: 34, SEQ ED NO: 36, SEQ ED
NO: 38, SEQ ED NO: 40, SEQ HD NO: 42, SEQ JD NO: 44, SEQ ID NO: 46, SEQ JD NO: 48, SEQ H NO: 50, SEQ ID NO: 52, SEQ ID NO: 54, or SEQ ED NO: 56;
(c) the amino acid sequence of SEQ ED NO: 59, SEQ ED NO: 61, SEQ ED NO: 63, SEQ ID NO: 65, SEQ ED NO: 67, SEQ JD NO: 69, SEQ ED NO: 71, SEQ ED NO: 73, SEQ ID NO: 75, SEQ ED NO: 77, SEQ ED NO: 79, SEQ ED NO: 81, SEQ ED NO: 83,
SEQ ED NO: 85, SEQ ED NO: 87, SEQ ED NO: 89, SEQ ID NO: 91, SEQ ED NO: 93, SEQ
125
ID NO: 95, SEQ JD NO: 97, SEQ JD NO: 99, SEQ ID NO: 101, SEQ ID NO: 103, SEQ ED
NO: 105, SEQ ID NO: 107, SEQ ID NO: 109, SEQ ED NO: 111, SEQ ED NO 113, SEQ ED NO: 115, SEQ ID NO: 117, SEQ ID NO: 119, SEQ ID NO: 121, SEQ ID NO 123, SEQ ED
NO: 125, SEQ ED NO: 127, SEQ ID NO: 129, SEQ HD NO: 131, SEQ JD NO 133, SEQ ED NO: 135, SEQ ID NO: 137, SEQ ID NO: 139, SEQ ED NO: 141, SEQ ED NO 143, SEQ ED
NO: 145, SEQ ED NO: 147, SEQ ED NO: 149, SEQ ED NO: 151, SEQ ED NO 153, SEQ ED NO: 155, SEQ ED NO: 157, SEQ ED NO: 159, SEQ ED NO: 161, SEQ ED NO 163, or SEQ ED NO: 165;
(d) the amino acid sequence of SEQ ID NO: 168, SEQ HD NO: 170, SEQ ED NO: 172, SEQ ED NO: 174, SEQ ED NO: 176, SEQ ED NO: 178, SEQ JD NO: 180, SEQ
ED NO: 182, SEQ ID NO: 184, SEQ HD NO: 186, SEQ ID NO: 188, SEQ HD NO: 190, SEQ ED NO: 192, SEQ HD NO: 194, SEQ HD NO: 196, SEQ HD NO: 198, SEQ ID NO: 200, SEQ ID NO: 202, SEQ JD NO: 204, SEQ ED NO: 206, SEQ ED NO: 208, SEQ ED NO: 210, SEQ ED NO: 212, SEQ ED NO: 214, or SEQ ED NO: 216, or SEQ ED NO: 218; or (e) the amino acid sequence of SEQ ED NO: 221, SEQ ID NO: 223, SEQ
ED NO: 225, SEQ ID NO: 227, SEQ ED NO: 229, SEQ ED NO: 231 , SEQ ED NO: 233, SEQ ED NO: 235, SEQ ED NO: 237, SEQ ED NO: 239, SEQ ED NO: 241 , SEQ ED NO: 243, SEQ ED NO: 245, SEQ JD NO: 247, SEQ JD NO: 249, SEQ JD NO: 251, SEQ ED NO: 253, SEQ HD NO: 255, SEQ JD NO: 257, SEQ ED NO: 259, SEQ ED NO: 261, SEQ ED NO: 263, SEQ ED NO: 265, or SEQ ED NO: 267.
34. The method of Claim 26, wherein the individual is a mammal.
35. The method of Claim 34, wherein the mammal is a human.
36. A method for treating, ameliorating, or preventing a protective sequence- mediated condition, disorder or disease in an individual comprising administering to the individual a compound which modulates the expression or activity of a protective sequence product and/or protective sequence regulatory product in the individual.
126
37. The method of Claim 36, wherein the compound inhibits the expression or activity of a protective sequence product and/or protective sequence regulatory product in the individual.
38. The method of Claim 36, wherein the compound enhances or potentiates the expression or activity of a protective sequence product and/or protective sequence regulatory product in the individual.
39. The method of Claim 36, wherein the compound is selected from the group consisting of a small organic molecule, an antibody, a ribozyme, an antisense molecule, and combinations thereof.
40. The method of Claim 36, wherein the protective sequence-mediated condition, disorder, or disease is a condition, disorder, or disease of the central nervous system.
41. The method of Claim 40, wherein the central nervous system condition is an ischemia-related condition.
42. The method of Claim 41, wherein the central nervous system condition is a stroke.
43. The method of Claim 36, wherein the protective sequence product comprises:
(a) the amino acid sequence of SEQ ID NO: 3, SEQ HD NO: 5, SEQ ED NO: 7, SEQ ED NO: 9, SEQ JD NO: 11, SEQ ED NO: 13, SEQ ID NO: 15, SEQ ID NO: 17, SEQ ID NO: 19, SEQ ED NO: 21, SEQ ED NO: 23, SEQ ED NO: 25, SEQ ED NO: 27, SEQ
ED NO: 29, or SEQ ID NO: 31 ;
(b) the amino acid sequence of SEQ ED NO: 34, SEQ ID NO: 36, SEQ ED NO: 38, SEQ ED NO: 40, SEQ ED NO: 42, SEQ ED NO: 44, SEQ ED NO: 46, SEQ ED NO: 48, SEQ ED NO: 50, SEQ ID NO: 52, SEQ ID NO: 54, or SEQ ED NO: 56; (c) the amino acid sequence of SEQ ID NO: 59, SEQ JD NO: 61, SEQ ED
NO: 63, SEQ HD NO: 65, SEQ ID NO: 67, SEQ ED NO: 69, SEQ ID NO: 71, SEQ ED NO:
127
73, SEQ ID NO: 75, SEQ ID NO: 77, SEQ ED NO: 79, SEQ ED NO: 81, SEQ ED NO: 83, SEQ ED NO: 85, SEQ ED NO: 87, SEQ ED NO: 89, SEQ ED NO: 91, SEQ ED NO: 93, SEQ ED NO: 95, SEQ ED NO: 97, SEQ ED NO: 99, SEQ ID NO: 101, SEQ JD NO: 103, SEQ ED NO: 105, SEQ ED NO: 107, SEQ ED NO: 109, SEQ ID NO: 111, SEQ ED NO: 113, SEQ ED NO: 115, SEQ ID NO: 117, SEQ ED NO: 119, SEQ ID NO: 121, SEQ HD NO: 123, SEQ ID
NO: 125, SEQ JD NO: 127, SEQ ID NO: 129, SEQ ID NO: 131, SEQ ED NO: 133, SEQ ED NO: 135, SEQ ED NO: 137, SEQ ED NO: 139, SEQ ED NO: 141, SEQ ID NO: 143, SEQ ED NO: 145, SEQ ED NO: 147, SEQ ED NO: 149, SEQ ED NO: 151, SEQ ED NO: 153, SEQ ED NO: 155, SEQ JD NO: 157, SEQ JD NO: 159, SEQ JD NO: 161, SEQ ED NO: 163, or SEQ ED NO: 165;
(d) the amino acid sequence of SEQ ID NO: 168, SEQ JD NO: 170, SEQ H NO: 172, SEQ ID NO: 174, SEQ JD NO: 176, SEQ HD NO: 178, SEQ ID NO: 180, SEQ ID NO: 182, SEQ ID NO: 184, SEQ ID NO: 186, SEQ ID NO: 188, SEQ HD NO: 190, SEQ ED NO: 192, SEQ ID NO: 194, SEQ ID NO: 196, SEQ JD NO: 198, SEQ ED NO: 200, SEQ ED NO: 202, SEQ ED NO: 204, SEQ ED NO: 206, SEQ ED NO: 208, SEQ JD NO: 210, SEQ
ED NO: 212, SEQ ED NO: 214, or SEQ ED NO: 216, or SEQ ED NO: 218; or
(e) the amino acid sequence of SEQ ED NO: 221, SEQ ED NO: 223, SEQ ED NO: 225, SEQ ED NO: 227, SEQ ED NO: 229, SEQ ED NO: 231 , SEQ ED NO: 233, SEQ ED NO: 235, SEQ ED NO: 237, SEQ ED NO: 239, SEQ ED NO: 241, SEQ ED NO: 243, SEQ ED NO: 245, SEQ ED NO: 247, SEQ ED NO: 249, SEQ ED NO: 251, SEQ ED NO: 253, SEQ
ED NO: 255, SEQ ED NO: 257, SEQ ID NO: 259, SEQ JD NO: 261, SEQ ED NO: 263, SEQ ID NO: 265, or SEQ ED NO: 267.
44. The method of Claim 36, wherein the individual is a mammal.
45. The method of Claim 44, wherein the mammal is a human.
46. A method for identifying a compound which modulates expression of a protective sequence comprising: (a) contacting a test compound to a cell that expresses a protective sequence;
(b) measuring a level of protective sequence expression in the cell;
(c) comparing the level of protective sequence expression in the cell in the presence of the test compound to a level of protective sequence expression in the cell in the absence of the test compound, wherein if the level of protective sequence expression in the cell in the presence of the test compound differs from the level of expression of the protective sequence in the cell in the absence of the test compound, a compound that modulates expression of a protective sequence is identified.
47. The method of Claim 46, wherein the protective sequence is endogenously expressed within the cell.
48. The method of Claim 46, wherein the protective sequence encodes a polypeptide comprising:
(a) the amino acid sequence of SEQ ED NO: 3, SEQ JD NO: 5, SEQ HD NO: 7, SEQ JD NO: 9, SEQ HD NO: 11, SEQ ED NO: 13, SEQ ED NO: 15, SEQ ED NO: 17,
SEQ ED NO: 19, SEQ ED NO: 21, SEQ ED NO: 23, SEQ ED NO: 25, SEQ ED NO: 27, SEQ ED NO: 29, or SEQ ED NO: 31;
(b) the amino acid sequence of SEQ ED NO: 34, SEQ JD NO: 36, SEQ ID NO: 38, SEQ JD NO: 40, SEQ ID NO: 42, SEQ JD NO: 44, SEQ JD NO: 46, SEQ ID NO: 48, SEQ ID NO: 50, SEQ JD NO: 52, SEQ JD NO: 54, or SEQ ED NO: 56;
(c) the amino acid sequence of SEQ ED NO: 59, SEQ ED NO: 61, SEQ ED NO: 63, SEQ ED NO: 65, SEQ ED NO: 67, SEQ ED NO: 69, SEQ ED NO: 71, SEQ ED NO: 73, SEQ ED NO: 75, SEQ ED NO: 77, SEQ ED NO: 79, SEQ ED NO: 81, SEQ ED NO: 83, SEQ ED NO: 85, SEQ ED NO: 87, SEQ ED NO: 89, SEQ ED NO: 91, SEQ ED NO: 93, SEQ ID NO: 95, SEQ ID NO: 97, SEQ ID NO: 99, SEQ ID NO: 101, SEQ ID NO: 103, SEQ ED
NO: 105, SEQ ED NO: 107, SEQ HD NO: 109, SEQ JD NO: 111, SEQ ID NO: 113, SEQ ED NO: 115, SEQ ED NO: 117, SEQ ED NO: 119, SEQ ID NO: 121, SEQ ED NO: 123, SEQ ID NO: 125, SEQ JD NO: 127, SEQ ED NO: 129, SEQ ED NO: 131, SEQ ED NO: 133, SEQ HD NO: 135, SEQ ED NO: 137, SEQ JD NO: 139, SEQ ID NO: 141, SEQ ED NO: 143, SEQ ED NO: 145, SEQ JD NO: 147, SEQ ID NO: 149, SEQ ED NO: 151, SEQ ED NO: 153, SEQ ED
NO: 155, SEQ ED NO: 157, SEQ ED NO: 159, SEQ ED NO: 161, SEQ ED NO: 163, or SEQ ED NO: 165;
129
(d) the amino acid sequence of SEQ ED NO: 168, SEQ JD NO: 170, SEQ ED NO: 172, SEQ ED NO: 174, SEQ ED NO: 176, SEQ ED NO: 178, SEQ ED NO: 180, SEQ E NO: 182, SEQ ID NO: 184, SEQ ED NO: 186, SEQ ID NO: 188, SEQ HD NO: 190, SEQ ED NO: 192, SEQ ED NO: 194, SEQ ED NO: 196, SEQ ED NO: 198, SEQ ED NO: 200, SEQ HD NO: 202, SEQ ED NO: 204, SEQ ED NO: 206, SEQ ED NO: 208, SEQ ED NO: 210, SEQ ED NO: 212, SEQ ED NO: 214, or SEQ ED NO: 216, or SEQ ED NO: 218; or
(e) the amino acid sequence of SEQ ED NO: 221, SEQ ED NO: 223, SEQ ED NO: 225, SEQ ED NO: 227, SEQ ID NO: 229, SEQ JD NO: 231 , SEQ JD NO: 233, SEQ ED NO: 235, SEQ ED NO: 237, SEQ ED NO: 239, SEQ ED NO: 241, SEQ ED NO: 243, SEQ ED NO: 245, SEQ ED NO: 247, SEQ ED NO: 249, SEQ ED NO: 251, SEQ ED NO: 253, SEQ ID NO: 255, SEQ JD NO: 257, SEQ HD NO: 259, SEQ ID NO: 261, SEQ ED NO: 263, SEQ ED NO: 265, or SEQ ED NO: 267.
49. The method of Claim 46, wherein the protective sequence comprises:
(a) the nucleic acid sequence of SEQ ID NO: 2, SEQ JD NO: 4, SEQ JD NO: 6, SEQ ED NO: 8, SEQ ED NO: 10, SEQ ED NO: 12, SEQ ED NO: 14, SEQ ED NO: 16, SEQ ED NO: 18, SEQ ED NO: 20, SEQ JD NO: 22, SEQ ED NO: 24, SEQ ED NO: 26, SEQ ED NO: 28, or SEQ ED NO: 30;
(b) the nucleic acid sequence of SEQ ED NO: 33, SEQ ED NO: 35, SEQ ED NO: 37, SEQ ED NO: 39, SEQ ED NO: 41, SEQ ED NO: 43, SEQ ED NO: 45, SEQ ED NO: 47, SEQ HD NO: 49, SEQ JD NO: 51, SEQ ED NO: SEQ ED NO: 53, or SEQ JD NO: 55;
(c) the nucleic acid sequence of SEQ ED NO: 58, SEQ JD NO: 60, SEQ ED NO: 62, SEQ ED NO: 64, SEQ ED NO: 66, SEQ ED NO: 68, SEQ ID NO: 70, SEQ ED NO: 72, SEQ ED NO: 74, SEQ ED NO: 76, SEQ ED NO: 78, SEQ ED NO: 80, SEQ ED NO: 82, SEQ ED NO: 84, SEQ ED NO: 86, SEQ ED NO: 88, SEQ ED NO: 90, SEQ JD NO: 92, SEQ HD NO: 94, SEQ ID NO: 96, SEQ JD NO: 98, SEQ ED NO: 100, SEQ JD NO: 102, SEQ ED
NO: 104, SEQ ED NO: 106, SEQ ED NO 108 SEQ ED NO: 1 10, SEQ ED NO: 112, SEQ ED NO: 114, SEQ JD NO: 116, SEQ JD NO 118, SEQ ED NO: 120, SEQ HD NO: 122, SEQ ED NO: 124, SEQ ID NO: 146, SEQ ED NO 148, SEQ ED NO: 130, SEQ ED NO: 132, SEQ ED NO: 134, SEQ ED NO: 136, SEQ ED NO 138, SEQ ED NO: 140, SEQ ED NO: 142, SEQ ED NO: 144, SEQ ED NO: 146, SEQ ID NO 148, SEQ ED NO: 150, SEQ ED NO: 152, SEQ ED
130
NO: 154, SEQ ID NO: 156, SEQ JD NO: 158, SEQ ID NO: 160, SEQ JD NO: 162, or SEQ ED NO: 164;
(d) the nucleic acid sequence of SEQ ED NO: 167, SEQ ED NO: 169, SEQ ED NO: 171, SEQ ED NO: 173, SEQ ED NO: 175, SEQ ED NO: 177, SEQ ED NO: 179, SEQ ID NO: 181, SEQ ID NO: 183, SEQ ID NO: 185, SEQ HD NO: 187, SEQ HD NO: 189, SEQ
H NO: 191, SEQ ED NO: 193, SEQ ED NO: 195, SEQ ED NO: 197, SEQ ED NO: 199, SEQ ED NO: 201, SEQ ED NO: 203, SEQ ED NO: 205, SEQ ED NO: 207, SEQ ED NO: 209, SEQ ED NO: 211, SEQ ED NO: 213, SEQ ED NO: 215, or SEQ ED NO: 217;
(e) the nucleic acid sequence of SEQ ED NO: 220, SEQ ED NO: 222, SEQ ED NO: 224, SEQ ED NO: 226, SEQ JD NO: 228, SEQ JD NO: 230, SEQ ID NO: 232, SEQ
ID NO: 234, SEQ JD NO: 236, SEQ ID NO: 238, SEQ ID NO: 240, SEQ ID NO: 242, SEQ HD NO: 244, SEQ ID NO: 246, SEQ ED NO: 248, SEQ ED NO: 250, SEQ ED NO: 252, SEQ HD NO: 254, SEQ JD NO: 256, SEQ JD NO: 258, SEQ ED NO: 260, SEQ ED NO: 262, SEQ ED NO: 264, or SEQ ED NO: 266; or (f) the nucleic acid sequence of SEQ ED NO: 1 , SEQ ED NO: 32, SEQ ED
NO: 57, SEQ JD NO: 166, or SEQ JD NO: 219.
50. A method for identifying a compound which modulates expression, function or activity of a protective sequence product or protective sequence regulatory element comprising:
(a) contacting a test compound to a cell that expresses a protective sequence product or protective sequence regulatory element;
(b) measuring a level of protective sequence product or protective sequence regulatory element expression, function or activity in the cell; (c) comparing the level of protective sequence product or protective sequence regulatory element expression, function or activity in the cell in the presence of the test compound to a level of protective sequence product or protective sequence regulatory element expression or activity in the cell in the absence of the test compound, wherein if the level of protective sequence product or protective sequence regulatory element expression, function or activity in the cell in the presence of the test compound differs from the level of protective sequence product or protective sequence regulatory
131
element expression, function or activity in the cell in the absence of the test compound, a compound that modulates expression or activity of a protective sequence product or protective sequence regulatory element is identified.
51. The method of Claim 50, wherein the protective sequence product or protective sequence regulatory element comprises:
(a) the nucleic acid sequence of SEQ ID NO: 2, SEQ ID NO: 4, SEQ HD NO: 6, SEQ ED NO: 8, SEQ ID NO: 10, SEQ ED NO: 12, SEQ ED NO: 14, SEQ ED NO: 16, SEQ ED NO: 18, SEQ JD NO: 20, SEQ JD NO: 22, SEQ ED NO: 24, SEQ ED NO: 26, SEQ ED NO: 28, or SEQ ID NO: 30;
(b) the nucleic acid sequence of SEQ ID NO: 33, SEQ ID NO: 35, SEQ JD NO: 37, SEQ ED NO: 39, SEQ ED NO: 41, SEQ ED NO: 43, SEQ JD NO: 45, SEQ JD NO: 47, SEQ ED NO: 49, SEQ ED NO: 51, SEQ ED NO: SEQ ED NO: 53, or SEQ ED NO: 55;
(c) the nucleic acid sequence of SEQ ED NO: 58, SEQ ED NO: 60, SEQ ED NO: 62, SEQ ED NO: 64, SEQ ED NO: 66, SEQ HD NO: 68, SEQ JD NO: 70, SEQ JD NO:
72, SEQ ED NO: 74, SEQ ED NO: 76, SEQ ED NO: 78, SEQ ED NO: 80, SEQ JD NO: 82, SEQ ED NO: 84, SEQ ED NO: 86, SEQ ED NO: 88, SEQ ED NO: 90, SEQ JD NO: 92, SEQ HD NO: 94, SEQ HD NO: 96, SEQ JD NO: 98, SEQ ED NO: 100, SEQ ED NO: 102, SEQ ED NO: 104, SEQ ED NO: 106, SEQ ED NO: 108 SEQ ID NO: 110, SEQ JD NO: 112, SEQ ED NO: 114, SEQ ED NO: 116, SEQ ED NO: 118, SEQ ED NO: 120, SEQ ED NO: 122, SEQ ED
NO: 124, SEQ ED NO: 146, SEQ ED NO: 148, SEQ ED NO: 130, SEQ JD NO: 132, SEQ JD NO: 134, SEQ JD NO: 136, SEQ ED NO: 138, SEQ ID NO: 140, SEQ JD NO: 142, SEQ JD NO: 144, SEQ ID NO: 146, SEQ JD NO: 148, SEQ ID NO: 150, SEQ JD NO: 152, SEQ JD NO: 154, SEQ ED NO: 156, SEQ ED NO: 158, SEQ ED NO: 160, SEQ ED NO: 162, or SEQ ED NO: 164;
(d) the nucleic acid sequence of SEQ ED NO: 167, SEQ ED NO: 169, SEQ ED NO: 171, SEQ JD NO: 173, SEQ JD NO: 175, SEQ ED NO: 177, SEQ ED NO: 179, SEQ ID NO: 181, SEQ JD NO: 183, SEQ ED NO: 185, SEQ ED NO: 187, SEQ JD NO: 189, SEQ HD NO: 191, SEQ ED NO: 193, SEQ ED NO: 195, SEQ ED NO: 197, SEQ JD NO: 199, SEQ ED NO: 201, SEQ ED NO: 203, SEQ JD NO: 205, SEQ JD NO: 207, SEQ ED NO: 209, SEQ
HD NO: 211, SEQ ED NO: 213, SEQ ED NO: 215, or SEQ ED NO: 217; or
132
(e) the nucleic acid sequence of SEQ ED NO: 220, SEQ ED NO: 222, SEQ ED NO: 224, SEQ ED NO: 226, SEQ JD NO: 228, SEQ ID NO: 230, SEQ ID NO: 232, SEQ ID NO: 234, SEQ ED NO: 236, SEQ ED NO: 238, SEQ ED NO: 240, SEQ ID NO: 242, SEQ ID NO: 244, SEQ ID NO: 246, SEQ HD NO: 248, SEQ ID NO: 250, SEQ ID NO: 252, SEQ ID NO: 254, SEQ JD NO: 256, SEQ ID NO: 258, SEQ ED NO: 260, SEQ ED NO: 262, SEQ
ED NO: 264, or SEQ ED NO: 266.
52. A method for transferring a protective sequence into a cell comprising contacting the cell with a nucleic acid comprising a protective sequence such that the protective sequence is transferred into the cell.
53. The method of Claim 52 wherein the protective sequence is expressed in the cell.
54. The method of Claim 52 wherein the protective sequence delays and/or prevents the cell from undergoing cell death.
55. A method for modulating the function, activity, expression and/or level of a protective sequence in a cell comprising administering to the cell a compound which modulates the function, activity, expression and/or level of a protective sequence in the cell.
56. The method of Claim 55, wherein the compound inhibits the function, activity, expression and/or level of a protective sequence in the cell.
57. The method of Claim 55, wherein the compound enhances or potentiates the function, activity, expression and/or level of a protective sequence in the cell.
58. The methods of any one of Claims 55-57, wherein the compound is selected from the group consisting of a small organic molecule, an antibody, a ribozyme, an antisense molecule, and combinations thereof.
133
59. The method of Claim 55, wherein the protective sequence encodes a polypeptide comprising:
(a) the amino acid sequence of SEQ ED NO: 3, SEQ ED NO: 5, SEQ ED NO: 7, SEQ ED NO: 9, SEQ ED NO: 11, SEQ ID NO: 13, SEQ ID NO: 15, SEQ ID NO: 17, SEQ H NO: 19, SEQ ED NO: 21, SEQ ED NO: 23, SEQ ED NO: 25, SEQ JD NO: 27, SEQ
H NO: 29, or SEQ ID NO: 31 ;
(b) the amino acid sequence of SEQ ED NO: 34, SEQ JD NO: 36, SEQ ED NO: 38, SEQ JD NO: 40, SEQ JD NO: 42, SEQ ED NO: 44, SEQ ED NO: 46, SEQ ED NO: 48, SEQ HD NO: 50, SEQ ED NO: 52, SEQ ED NO: 54, or SEQ ED NO: 56; (c) the amino acid sequence of SEQ ED NO: 59, SEQ HD NO: 61, SEQ ED
NO: 63, SEQ ED NO: 65, SEQ JD NO: 67, SEQ JD NO: 69, SEQ ED NO: 71, SEQ ED NO: 73, SEQ ED NO: 75, SEQ ED NO: 77, SEQ ED NO: 79, SEQ ED NO: 81, SEQ ED NO: 83, SEQ ED NO: 85, SEQ ED NO: 87, SEQ ID NO: 89, SEQ HD NO: 91, SEQ ID NO: 93, SEQ HD NO: 95, SEQ JD NO: 97, SEQ JD NO: 99, SEQ ED NO: 101, SEQ ED NO: 103, SEQ ED NO: 105, SEQ JD NO: 107, SEQ HD NO: 109, SEQ ID NO: 111, SEQ ID NO: 113, SEQ ID
NO: 115, SEQ JD NO: 117, SEQ HD NO: 119, SEQ ED NO: 121, SEQ ED NO: 123, SEQ ED NO: 125, SEQ ID NO: 127, SEQ ID NO: 129, SEQ ID NO: 131 , SEQ ED NO: 133, SEQ ED NO: 135, SEQ JD NO: 137, SEQ ED NO: 139, SEQ ID NO: 141, SEQ JD NO: 143, SEQ ED NO: 145, SEQ ED NO: 147, SEQ JD NO: 149, SEQ ID NO: 151, SEQ ED NO: 153, SEQ ED NO: 155, SEQ ED NO: 157, SEQ ED NO: 159, SEQ ED NO: 161, SEQ ED NO: 163, or SEQ
ED NO: 165;
(d) the amino acid sequence of SEQ ED NO: 168, SEQ JD NO: 170, SEQ ED NO: 172, SEQ ID NO: 174, SEQ ED NO: 176, SEQ ED NO: 178, SEQ ID NO: 180, SEQ ED NO: 182, SEQ ED NO: 184, SEQ ED NO: 186, SEQ ED NO: 188, SEQ ED NO: 190, SEQ ID NO: 192, SEQ JD NO: 194, SEQ JD NO: 196, SEQ JD NO: 198, SEQ JD NO: 200, SEQ
HD NO: 202, SEQ ID NO: 204, SEQ HD NO: 206, SEQ ED NO: 208, SEQ ED NO: 210, SEQ ED NO: 212, SEQ ED NO: 214, or SEQ ED NO: 216, or SEQ JD NO: 218; or
(e) the amino acid sequence of SEQ ED NO: 221, SEQ JD NO: 223, SEQ ID NO: 225, SEQ ID NO: 227, SEQ JD NO: 229, SEQ ED NO: 231, SEQ JD NO: 233, SEQ HD NO: 235, SEQ ID NO: 237, SEQ JD NO: 239, SEQ ED NO: 241, SEQ ED NO: 243, SEQ
ED NO: 245, SEQ D NO: 247, SEQ ED NO: 249, SEQ ED NO: 251, SEQ ED NO: 253, SEQ
134
AMENDED SHEET {ARTICLE 19)
ED NO: 255, SEQ ED NO: 257, SEQ ED NO: 259, SEQ ED NO: 261, SEQ ED NO: 263, SEQ ID NO: 265, or SEQ ED NO: 267.
60. A primer comprising an isolated nucleic acid molecule which hybridizes under highly stringent conditions to:
(a) the nucleic acid sequence of SEQ ED NO: 2, SEQ ED NO: 4, SEQ ED NO: 6, SEQ ED NO: 8, SEQ ED NO: 10, SEQ ED NO: 12, SEQ ED NO: 14, SEQ ED NO: 16, SEQ ED NO: 18, SEQ ID NO: 20, SEQ JD NO: 22, SEQ ID NO: 24, SEQ ED NO: 26, SEQ ED NO: 28, or SEQ ID NO: 30; (b) the nucleic acid sequence of SEQ ED NO: 33, SEQ ED NO: 35, SEQ ED
NO: 37, SEQ ED NO: 39, SEQ ED NO: 41, SEQ ED NO: 43, SEQ ED NO: 45, SEQ ED NO: 47, SEQ ED NO: 49, SEQ ED NO: 51, SEQ ED NO: SEQ ED NO: 53, or SEQ ED NO: 55;
(c) the nucleic acid sequence of SEQ ED NO: 58, SEQ JD NO: 60, SEQ ED NO: 62, SEQ JD NO: 64, SEQ JD NO: 66, SEQ ED NO: 68, SEQ ID NO: 70, SEQ ID NO: 72, SEQ ED NO: 74, SEQ ED NO: 76, SEQ ED NO: 78, SEQ ED NO: 80, SEQ JD NO: 82,
SEQ ED NO: 84, SEQ ID NO: 86, SEQ JD NO: 88, SEQ ID NO: 90, SEQ JD NO: 92, SEQ ID NO: 94, SEQ ED NO: 96, SEQ ED NO: 98, SEQ ED NO: 100, SEQ ED NO: 102, SEQ ID NO: 104, SEQ ID NO: 106, SEQ ID NO: 108 SEQ ED NO: 110, SEQ ID NO: 112, SEQ ED NO: 114, SEQ JD NO: 116, SEQ JD NO: 118, SEQ ID NO: 120, SEQ ID NO: 122, SEQ ID NO: 124, SEQ ED NO: 146, SEQ ID NO: 148, SEQ ED NO: 130, SEQ ID NO: 132, SEQ HD
NO: 134, SEQ ID NO: 136, SEQ JD NO: 138, SEQ ED NO: 140, SEQ ID NO: 142, SEQ ED NO: 144, SEQ JD NO: 146, SEQ ID NO: 148, SEQ ID NO: 150, SEQ JD NO: 152, SEQ JD NO: 154, SEQ ED NO: 156, SEQ JD NO: 158, SEQ ED NO: 160, SEQ ID NO: 162, or SEQ ID NO: 164; (d) the nucleic acid sequence of SEQ ID NO: 167, SEQ JD NO: 169, SEQ
ID NO: 171, SEQ HD NO: 173, SEQ JD NO: 175, SEQ JD NO: 177, SEQ HD NO: 179, SEQ ID NO: 181, SEQ ID NO: 183, SEQ ID NO: 185, SEQ ID NO: 187, SEQ ID NO: 189, SEQ ID NO: 191, SEQ JD NO: 193, SEQ ED NO: 195, SEQ ED NO: 197, SEQ ED NO: 199, SEQ ED NO: 201, SEQ JD NO: 203, SEQ JD NO: 205, SEQ HD NO: 207, SEQ ID NO: 209, SEQ HD NO: 211, SEQ JD NO: 213, SEQ ED NO: 215, or SEQ ED NO: 217;
135
(e) the nucleic acid sequence of SEQ ED NO: 220, SEQ JD NO: 222, SEQ HD NO: 224, SEQ ED NO: 226, SEQ ED NO: 228, SEQ ED NO: 230, SEQ ED NO: 232, SEQ ED NO: 234, SEQ ED NO: 236, SEQ ED NO: 238, SEQ ED NO: 240, SEQ ED NO: 242, SEQ JD NO: 244, SEQ JD NO: 246, SEQ ED NO: 248, SEQ ED NO: 250, SEQ ED NO: 252, SEQ ED NO: 254, SEQ ED NO: 256, SEQ ED NO: 258, SEQ ED NO: 260, SEQ JD NO: 262, SEQ
ID NO: 264, or SEQ ED NO: 266; or
(f) the nucleic acid sequence of SEQ JD NO: 1 , SEQ JD NO: 32, SEQ ED NO: 57, SEQ ED NO: 166, or SEQ ED NO: 219.
61. A method for diagnosing a protective sequence-mediated condition, disorder or disease in an individual comprising obtaining a biological sample from said individual; contacting said biological sample with the primer according to claim 60; wherein if said primer interacts with said biological sample, but does not interact with a biological sample from a control individual not undergoing a protective sequence-mediated condition, disorder or disease, then a protective sequence-mediated condition, disorder or disease has been diagnosed.
62. A diagnostic kit for detecting a protective sequence-mediated condition, disorder or disease in an individual comprising a reagent in suitable packaging, wherein said reagent comprises the primer according to claim 60.
136